Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancerRavi A. Madan, William L. Dahut, Fatima Karzai et al.|British Journal of Urology|2020Cited by 13
Efficacy of abiraterone and enzalutamide in patients who had disease progression within twelve months of completing docetaxel for metastatic castration sensitive prostate cancer.Gang Chen, Ravi A. Madan, David James VanderWeele et al.|Journal of Clinical Oncology|2019Cited by 3
A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).Munjid Al Harthy, William L. Dahut, Ravi A. Madan et al.|Journal of Clinical Oncology|2019Cited by 3
Intermittent short course enzalutamide in biochemically recurrent prostate cancer: Analysis of PSA recovery, testosterone levels and tolerabilityMunjid Al Harthy, Ravi A. Madan, Harbhej Singh et al.|Annals of Oncology|2018Cited by 1
PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC).Mohammad Atiq, Ravi A. Madan, Shruti U. Gandhy et al.|Journal of Clinical Oncology|2022Cited by 1